Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05125588
Other study ID # FM-MEL
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 29, 2014
Est. completion date February 26, 2014

Study information

Verified date November 2021
Source Joint Stock Company "Farmak"
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence. The test product, Reumoxicam® 15 mg tablets (Farmak PJSC, Ukraine), given in a single dose was compared with a licensed reference product Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece), in a randomized, laboratory-blind, single dose, two periods, crossover study. The secondary objective of the trial was to investigate the safety of both preparations on the basis of safety clinical and laboratory examinations (at the beginning and at the end of the trial) and registration of adverse events and/ or adverse drug reactions.


Description:

Randomized, single-dose, crossover, two-period, two-sequence, laboratory-blinded, comparative bioavailability study of test medicinal product Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine) and reference medicinal product Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece) in healthy volunteers under fasting condition. During each period 18 blood samples were taken: before dosing (0) and then at: 0.5; 1; 2; 3; 4; 4.5; 5; 5.5; 6; 7; 8; 10; 12; 24; 36; 48 and 72 hours after dosing.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date February 26, 2014
Est. primary completion date February 26, 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy volunteers, men and women aged 18 to 45 years (inclusive); 2. Provided written Informed Consent Form of a Healthy Volunteer for Participation in the Clinical Study before the beginning of any screening procedures; 3. Ability (to the opinion of the investigator) to fulfill all requirements of the Study Protocol, i.e. the volunteer's ability for adequate collaboration; 4. Body mass index is within the limits (> 18,5 kg/m2 and < 30,0 kg/m2); 5. Persons free from any acute and chronic diseases of cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, and respiratory system; 6. Results of physical, instrumental, and laboratory examination of volunteers are within the normal limits, or any deviations are classified by the investigator as clinically irrelevant; 7. Chest fluorography or radiography results are within the normal limits (the examination should be carried out no earlier than 9 months before the screening moment), or any deviation is classified by the investigator as clinically irrelevant; 8. Women and men have to use medically confirmed barrier method of contraception during the whole study period; 9. Volunteers have to be non-smokers or smoke up to 10 cigarettes a day inclusive; 10. Volunteers need to undertake to follow all general diet limitations during the whole study period. Exclusion Criteria: 1. Subjects with evidence or suspicion of any relevant clinical abnormality (as based on medical history, physical examination, vital signs, chest X-ray, and 12-lead ECG) 2. Known hypersensitivity to meloxicam and/or other investigational products ingredients; 3. Compromised allergologic history; 4. Subjects who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs; 5. Active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months; 6. Subjects with peripheral oedema; 7. Any previously incurred diseases or surgical interventions which, to the investigator's opinion, may affect pharmacokinetics of the investigational product; 8. Positive result of HIV, syphilis, hepatitis B and C markets test; 9. Positive result of urine test for narcotic substances (amphetamine, metamphetamine, morphine, marijuana, cocaine); 10. Positive result of alcohol vapors test in expired air; 11. Pregnancy (positive result of urine pregnancy test in women) and lactation period; 12. Incurred acute infectious diseases within 28 days before beginning of the study; 13. Use of any medicinal products within 14 days before beginning of the study; 14. Blood donation or blood loss of more than 300 ml in less than 30 days before beginning of the study; 15. Participation in any other clinical study during the last 90 days before beginning of the study; 16. Other reasons which, to the investigator's opinion, make the volunteer's participation in the study undesirable.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine)
One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece)
One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Joint Stock Company "Farmak"

Outcome

Type Measure Description Time frame Safety issue
Primary AUC0-t Area under the plasma concentration-time curve from time zero to time t of the last quantifiable concentration up to 72 hours post-administration
Primary Cmax Maximum drug concentration in plasma up to 72 hours post-administration
Secondary AUC0-inf Area under the plasma concentration-time curve from time zero to infinity up to 72 hours post-administration
Secondary tmax time after administration to reach maximum drug concentration in plasma up to 72 hours post-administration
Secondary t1/2 elimination half-life up to 72 hours post-administration
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3